GI
VRDN icon

GAMMA Investing’s Viridian Therapeutics VRDN Stock Holding History

GAMMA Investing’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.49K Buy
462
+4
+0.9% +$64 ﹤0.01% 3286
2026
Q1 		$8.96K Sell
458
-19
-4% -$564 ﹤0.01% 3120
2025
Q4 		$14.8K Buy
477
+165
+53% +$4.53K ﹤0.01% 2780
2025
Q3 		$6.73K Sell
312
-9
-3% -$162 ﹤0.01% 3058
2025
Q2 		$4.49K Sell
321
-304
-49% -$4.13K ﹤0.01% 3167
2025
Q1 		$8.43K Buy
625
+414
+196% +$7.05K ﹤0.01% 2833
2024
Q4 		$4.04K Buy
211
+24
+13% +$522 ﹤0.01% 2999
2024
Q3 		$4.25K Buy
187
+176
+1,600% +$2.88K ﹤0.01% 2811
2024
Q2 		$143 Sell
11
-95
-90% -$1.31K ﹤0.01% 3389
2024
Q1 		$1.86K Buy
106
+73
+221% +$1.42K ﹤0.01% 2767
2023
Q4 		$635 Buy
+33
New +$521 ﹤0.01% 2909

Other funds holding VRDN

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SOAM
SBI Okasan Asset Management Tokyo, Japan $3.04B AUM
NFG
Nations Financial Group Cedar Rapids, Iowa $2.09B AUM 34.27% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

GAMMA Investing's VRDN Position: Q2 2026 in Review

GAMMA Investing increased its Viridian Therapeutics (VRDN) stake by 0.87% in Q2 2026, buying an estimated $64 and bringing the position to 462 shares worth $8.49K. The position accounts for ﹤0.01% of the portfolio, ranked #3286.

GAMMA Investing first reported a position in VRDN in Q4 2023 and has held it in 11 quarters since. The position peaked at $14.8K in Q4 2025. 22 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • GAMMA Investing held 462 shares of Viridian Therapeutics worth $8.49K as of Q2 2026.
  • GAMMA Investing bought 4 Viridian Therapeutics shares in Q2 2026, an estimated $64.
  • Viridian Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3286 holding.
  • GAMMA Investing first reported a position in Viridian Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • GAMMA Investing's Viridian Therapeutics position peaked at $14.8K in Q4 2025.
  • 22 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.